Cargando…

Role of VEGFR‐1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib

The vascular endothelial growth factor receptor‐1 (VEGFR‐1) is a tyrosine kinase receptor frequently expressed in melanoma. Its activation by VEGF‐A or placental growth factor (PlGF) promotes tumour cell survival, migration and invasiveness. Moreover, VEGFR‐1 stimulation contributes to pathological...

Descripción completa

Detalles Bibliográficos
Autores principales:	Atzori, Maria Grazia, Ceci, Claudia, Ruffini, Federica, Trapani, Mauro, Barbaccia, Maria Luisa, Tentori, Lucio, D'Atri, Stefania, Lacal, Pedro Miguel, Graziani, Grazia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6933379/ https://www.ncbi.nlm.nih.gov/pubmed/31758648 http://dx.doi.org/10.1111/jcmm.14755

Ejemplares similares

Neuropilin-1 expressing melanoma cells as a model to study the aggressiveness of metastatic melanoma
por: Ruffini, Federica, et al.
Publicado: (2015)

Platelet-derived growth factor-C promotes human melanoma aggressiveness through activation of neuropilin-1
por: Ruffini, Federica, et al.
Publicado: (2017)

The Anti-Vascular Endothelial Growth Factor Receptor 1 (VEGFR-1) D16F7 Monoclonal Antibody Inhibits Melanoma Adhesion to Soluble VEGFR-1 and Tissue Invasion in Response to Placenta Growth Factor
por: Atzori, Maria Grazia, et al.
Publicado: (2022)

Antitumor activity of a novel anti-vascular endothelial growth factor receptor-1 monoclonal antibody that does not interfere with ligand binding
por: Graziani, Grazia, et al.
Publicado: (2016)

Role of VEGFs/VEGFR-1 Signaling and Its Inhibition in Modulating Tumor Invasion: Experimental Evidence in Different Metastatic Cancer Models
por: Ceci, Claudia, et al.
Publicado: (2020)

The anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cells
por: Atzori, Maria Grazia, et al.
Publicado: (2017)

Targeting Tumor-Associated Macrophages to Increase the Efficacy of Immune Checkpoint Inhibitors: A Glimpse into Novel Therapeutic Approaches for Metastatic Melanoma
por: Ceci, Claudia, et al.
Publicado: (2020)

Targeting the PTTG1 oncogene impairs proliferation and invasiveness of melanoma cells sensitive or with acquired resistance to the BRAF inhibitor dabrafenib
por: Caporali, Simona, et al.
Publicado: (2017)

Melanoma cells with acquired resistance to dabrafenib display changes in miRNA expression pattern and respond to this drug with an increase of invasiveness, which is abrogated by inhibition of NF-κB or the PI3K/mTOR signalling pathway
por: Caporali, Simona, et al.
Publicado: (2015)

Identification of Dihydrolipoamide Dehydrogenase as Potential Target of Vemurafenib-Resistant Melanoma Cells
por: Tabolacci, Claudio, et al.
Publicado: (2022)

Experimental Evidence of the Antitumor, Antimetastatic and Antiangiogenic Activity of Ellagic Acid
por: Ceci, Claudia, et al.
Publicado: (2018)

Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib
por: Queirolo, Paola, et al.
Publicado: (2016)

Ellagic Acid Inhibits Bladder Cancer Invasiveness and In Vivo Tumor Growth
por: Ceci, Claudia, et al.
Publicado: (2016)

Melanoma Cell Resistance to Vemurafenib Modifies Inter-Cellular Communication Signals
por: Tabolacci, Claudio, et al.
Publicado: (2021)

Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2
por: Lisi, Lucia, et al.
Publicado: (2020)

Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells()
por: Mologni, Luca, et al.
Publicado: (2018)

Imaging markers of response to combined BRAF and MEK inhibition in BRAF mutated vemurafenib-sensitive and resistant melanomas
por: Acciardo, Stefania, et al.
Publicado: (2018)

NF-κB is activated in response to temozolomide in an AKT-dependent manner and confers protection against the growth suppressive effect of the drug
por: Caporali, Simona, et al.
Publicado: (2012)

Neuropilin-1 as Therapeutic Target for Malignant Melanoma
por: Graziani, Grazia, et al.
Publicado: (2015)

miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A
por: Caporali, Simona, et al.
Publicado: (2019)

Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma
por: Piejko, Karolina, et al.
Publicado: (2023)

T cell therapy in combination with Vemurafenib in BRAF mutated metastatic melanoma patients
por: Borch, Troels Holz, et al.
Publicado: (2014)

Increased inflammatory lipid metabolism and anaplerotic mitochondrial activation follow acquired resistance to vemurafenib in BRAF-mutant melanoma cells
por: Delgado-Goñi, Teresa, et al.
Publicado: (2019)

Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma
por: Fisher, Rosalie, et al.
Publicado: (2012)

Vemurafenib: First-in-Class BRAF-Mutated Inhibitor for the Treatment of Unresectable or Metastatic Melanoma
por: Shelledy, Lindsay, et al.
Publicado: (2015)

Lack of Response to Vemurafenib in Melanoma Carrying BRAF K601E Mutation
por: Moiseyenko, Fedor V., et al.
Publicado: (2019)

Kisspeptin-mediated improvement of sensitivity to BRAF inhibitors in vemurafenib-resistant melanoma cells
por: Guzzetti, Carlotta, et al.
Publicado: (2023)

Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours
por: Tate, Sonya C, et al.
Publicado: (2016)

Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas
por: Sponghini, Andrea P, et al.
Publicado: (2015)

Vemurafenib enhances MHC induction in BRAF(V600E) homozygous melanoma cells
por: Sapkota, Bishu, et al.
Publicado: (2013)

Tracking of Glycans Structure and Metallomics Profiles in BRAF Mutated Melanoma Cells Treated with Vemurafenib
por: Nisiewicz, Monika K., et al.
Publicado: (2021)

Evolving Acquired Vemurafenib Resistance in a BRAF V600E Mutant Melanoma PDTX Model to Reveal New Potential Targets
por: Tóvári, József, et al.
Publicado: (2023)

Stat3 targeted therapies overcome the acquired resistance to vemurafenib in melanomas
por: Liu, Fang, et al.
Publicado: (2013)

Increased CD271 expression by the NF-kB pathway promotes melanoma cell survival and drives acquired resistance to BRAF inhibitor vemurafenib
por: Lehraiki, Abdelali, et al.
Publicado: (2015)

Skin toxicity in BRAF(V600) mutated metastatic cutaneous melanoma patients treated with vemurafenib
por: Nowara, Elzbieta, et al.
Publicado: (2016)

Ocular Changes in Metastatic Melanoma Patients Treated with MEK Inhibitor Cobimetinib and BRAF Inhibitor Vemurafenib
por: Gavric, Ana Ursula, et al.
Publicado: (2018)

Durable Response to Vemurafenib and Cobimetinib for the Treatment of BRAF-Mutated Metastatic Melanoma in Routine Clinical Practice
por: Álamo, Mª del Carmen, et al.
Publicado: (2021)

Inhibition of Patched Drug Efflux Increases Vemurafenib Effectiveness against Resistant Braf(V600E) Melanoma
por: Signetti, Laurie, et al.
Publicado: (2020)

The outcomes of Polish patients with advanced BRAF-positive melanoma treated with vemurafenib in a safety clinical trial
por: Rutkowski, Piotr, et al.
Publicado: (2015)

Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma
por: Amin, Asim, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_a3vjhpovtndprq953et2akvqq0